Presented by: Michael Grunkin, PhD
CEO and Co-Founder of Visiopharm
Learn more about Michael
Date January 9th, 2014 at 7 AM PST/ 10:00 AM EST/ 4 PM CET
Register at: https://www1.gotomeeting.com/register/733392449
About the Webinar:
The practice of histopathology faces several challenges; specifically an increasing number of cases that must be processed and diagnosed faster while reducing cost. At the same time pathologists and scientists are challenged, especially on data quality, by competing diagnostic modalities such as gene expression assays.
In order for histopathology to stay competitive and relevant, the quality of diagnostic data generated must improve while reducing costs and improving turnaround times. Recent research has identified automated, robust and reliable tumor cell detection as a pivotal tool both for improving of data quality and for enabling automation. This webinar will present new technology, methods, and workflows that have the potential to achieve these important goals.
- Introduce Virtual Double Staining (VDS) for tumor cell identification and compare it to other approaches of tumor cell identification including pattern recognition.
- Demonstrate how Virtual Double Staining has been implemented to support a highly automated, intuitive, and efficient diagnostic workflow.
- Show clinical validation results obtained for Ki67, PHH3, and hormone receptors in collaboration with the NordiQC. For Ki67, a statistically significant improvement in reproducibility was achieved and the results will be presented.
- A brief overview of a national Danish initiative that is underway to identify and quantify cost savings around pathology services.